Researchers at Stanford have facilitated active agent passage across the blood-brain barrier (BBB) by conjugating the active agent with a plasma protein that gets taken up by microglia.
Stanford inventors have developed a nanoparticle containing the toll-like receptor agonist (TLR7-NP) that elicits a potent anti-tumor immune response in multiple cancer types without inducing undesired systemic inflammation and toxicity.
Stanford researchers have developed a nanoparticle adjuvant with spatiotemporal controlled release of TLR7 agonist for broad protection against influenza or SARS-CoV-2.
The Stanford Sarafan ChEM-H Medicinal Chemistry Knowledge Center has developed a novel aqueous solubilizing promoiety (Sol-moiety) that can be readily attached to a wide-range of functional groups and undergo controlled cleavage to improve the pharmacokinetic profile of a desi
Stanford inventors have devised a method of multiplexing droplet reactions to analyze and identify many reactions in parallel on a single microfluidic chip using off-the-shelf flow control and valving.
Background: Researchers at Stanford have discovered a method to create lattice microneedle structures using high resolution continuous liquid interface printing (CLIP) technology.
Researchers at Stanford have invented a novel hydrogel with enhanced retention and extended durability. This hydrogel can be held together three times longer than many alternatives without sacrificing its self-healing attributes during injection.
Researchers at Stanford have developed a novel cell-free stem cell derived extracellular vesicle (EV) therapy powered by pulsed focused ultrasound (pFUS) that enhances its therapeutic and bioenergetic effect.
Researchers in Prof. Mark Kay's laboratory have developed variant AAV (adeno-associated virus) vectors with specificity and high transduction efficiency for pancreatic alpha- and beta- islet cells.
Stanford researchers have invented a method and developed compositions of matter to reduce the production of infectious viruses in cells that line the respiratory tract. The invention enables the use of gene-silencing approaches to prevent and treat viral infections.
The Hu Lab at Stanford has developed a neuroprotective gene therapy for treating glaucoma and other optic neuropathies. Their gene therapy AAV vector expresses NMNAT2 operably linked to a retinal ganglion cell-specific promoter (mSngc).
Researchers at Stanford have developed a CRISPR-based system to degrade viral RNA, with potential applications as both an anti-viral therapeutic and a prophylactic treatment against influenza, SARS-CoV-2, and other viruses.
Adeno-associated virus (AAV) vectored products are currently leading candidates for gene therapy applications with multiple approved products and many more in clinical trials.